The observation that the lowering of plasma glucocorticoid levels and GR signaling through metyrapone treatment did not also reduce the hyperlipidemia extent may thus perhaps underlie the unexpected overall null effect on atherosclerosis outcome. The gene discussed is NR3C1; the disease is hyperlipidemia.